Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1626 1629
This examiner grants 56% of resolved cases
Paul Randall Gauger examines applications in Tech Center 1600 and Art Unit 1626. With 25 resolved cases, the examiner has an allowance rate of 56.0%, showing a balanced distribution between grants and abandonments. This moderate rate suggests that while success is possible, applicants must be prepared for a rigorous examination process.
Interviews appear to be a beneficial tactic, as evidenced by an interview lift of 12.1%. This suggests that direct communication can help clarify issues and move the application toward a grant more effectively than written correspondence alone. The positive lift indicates that the examiner is open to dialogue and that oral advocacy can improve the chances of a favorable outcome.
The median days to allowance is 1280. This timeline is consistent with the complex subject matter often found in Tech Center 1600, requiring over three years to reach a final resolution. Practitioners should plan for a multi-year prosecution cycle and consider using interviews as a tool to navigate the examiner's requirements more efficiently.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19574713 | TRIAZOLOPYRIDINYL ETHER LINKED COMPOUNDS AS KINASE INHIBITORS | Non-Final OA | Bristol-Myers Squibb Company |
| 18042931 | METHODS TO PREVENT HIGH-GRADE SEROUS OVARIAN CANCER AND BREAST CANCER BY ADMINISTERING ANTIPROGESTINS | Final Rejection | The Trustees of Indiana University |
| 18454315 | BENZOTHIAZOLYL BICYCLO[1.1.1]PENTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | Non-Final OA | Hoffmann-La Roche Inc. |
| 18559655 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Non-Final OA | CORNELL UNIVERSITY |
| 17638669 | A PHARMACEUTICAL COMPOSITION FOR TREATING CANCER USED FOR A PATIENT HAVING SPECIFIC GENETIC MARKER | Final Rejection | J-PHARMA CO., LTD. |
| 18605444 | PRODRUGS OF BORON COMPOUNDS AND THEIR USE IN TREATING BACTERIAL INFECTIONS | Non-Final OA | SHANGHAI MICURX PHARMACEUTICALS CO., LTD. |
| 18605432 | METHODS AND USES OF BORON COMPOUNDS IN THE TREATMENT OF NONTUBERCULOUS MYCOBACTERIUM INFECTIONS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF SAME | Non-Final OA | MICURX PHARMECEUTICALS, INC. |
| 18468510 | HAPH ANALOGS AND THERAPEUTIC AND DIAGNOSTIC USES THEREOF | Non-Final OA | Medical Research & Consulting Services, LLC |
| 18272939 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Final Rejection | Yanping KONG |
| 17764003 | METHODS FOR TREATING HYPERPHENYLALANINEMIA | Final Rejection | PTC Therapeutics MP, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy